BioPharmSignal logoBioPharmSignal

Biotech News

Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)

Paratek Pharmaceuticals (PRTK)Paratek Pharmaceuticals2026-06-25 13:46 ESTCommercial

Oct. 3 Webinar Features Presentations by Scientific Leaders in NTM and Paratek's Management Team

BOSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for...

Open original release

Related news

PRTKParatek Pharmaceuticals2026-06-25 13:46 EST

Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022

PRTKParatek Pharmaceuticals2026-06-25 13:46 EST

Paratek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3

PRTKParatek Pharmaceuticals2026-06-25 13:46 EST

Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA® (omadacycline) under BARDA Project BioShield Contract

PRTKParatek Pharmaceuticals2026-06-25 13:46 EST

Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference

PRTKParatek Pharmaceuticals2026-06-25 13:46 EST

Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million

PRTKParatek Pharmaceuticals2026-06-25 13:46 EST

Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

PRTKParatek Pharmaceuticals2026-06-25 13:46 EST

Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield

PRTKParatek Pharmaceuticals2026-06-25 13:46 EST

Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board

PRTKParatek Pharmaceuticals2026-06-25 13:46 EST

Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract

PRTKParatek Pharmaceuticals2026-06-25 13:46 EST

Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China's National Reimbursement Drug List (NRDL)

View all latest news

Paratek Pharmaceuticals

Paratek Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

PRTKParatek Pharmaceuticals2026-06-26 11:31 EST

Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)

PRTKParatek Pharmaceuticals2026-06-26 11:31 EST

Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022

PRTKParatek Pharmaceuticals2026-06-26 11:31 EST

Paratek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3

PRTKParatek Pharmaceuticals2026-06-26 11:31 EST

Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA® (omadacycline) under BARDA Project BioShield Contract

PRTKParatek Pharmaceuticals2026-06-26 11:31 EST

Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States